ROVI Rebrands as ROIS, Acquires U.S. Injectable Manufacturing Site - Contract Pharma
ROVI Rebrands as ROIS, Acquires U.S. Injectable Manufacturing Site - Contract Pharma — regulatory update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 17, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (API & contract manufacturers) should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears. Bookmark this briefing, share it with anyone on your team responsible for compliance, and check the source link above for the full official text before you make any decisions.
What changed
ROVI Rebrands as ROIS, Acquires U.S. Injectable Manufacturing Site - Contract Pharma
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (API & contract manufacturers)
What you must do
Note this update; no immediate action appears required, but monitor for follow-on rules.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Medical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices
- Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Guidance for Industry; Availability
- Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - dykema.com
- Pfizer is Latest Target of FDA's Crackdown on Direct-to-Consumer, Social Media Ads - law.com
- Replimune gets FDA review for melanoma drug after prior setbacks - The Pharma Letter